Finding a consensus on utilising triplet therapy in mHSPC patients

Finding a consensus on utilising triplet therapy in metastatic hormone sensitive cancer (mHSPC) patients, an expert panel discussion.

In this thought-provoking discussion at P3 Prostate Cancer Forum 2025, esteemed panellists engaged with the audience on key clinical controversies within metastatic prostate cancer treatment.

They tackle pivotal questions, such as whether triplet therapy (androgen deprivation therapy (ADT) plus docetaxel plus androgen receptor pathway inhibitor (ARPI)) should be recommended for patients with metachronous low-burden mHSPC, and which ARPI is preferable for those with a history of cognitive impairment, fatigue, or fall?

By examining these insights, healthcare professionals can gain a deeper understanding of how the consensus statements can be applied to enhance clinical practice and improve patient outcomes.